Can You Get Paid to Donate Poop? Stool Bank Pay Rates and Screening

Yes, you can get paid to donate poop, but only through a licensed stool bank or an academic transplant program. Most US programs pay USD 25 to USD 50 per donation and cap monthly earnings at USD 200 to USD 500. They also accept fewer than 3 in 100 applicants after screening. In practice the money is compensation for time and travel, not a purchase of your stool. A committed donor who qualifies can earn roughly USD 1,000 to USD 6,000 a year. Many qualified donors earn nothing at all, because hospital programs reimburse expenses only.

How a Stool Donation Becomes a Treatment

Fecal microbiota transplantation, or FMT, moves processed stool from a screened donor into a patient's colon. The delivery route is a colonoscope, an enema, or a swallowed capsule. The active ingredient is not the stool itself but the live bacterial community inside it, roughly 10^11 to 10^12 microbial cells per gram of wet material. That density is why a single bowel movement can treat more than one patient.

The target disease explains why donors are needed at all. Clostridioides difficile infection is a dysbiosis problem, not a simple contamination event. A course of antibiotics wipes out much of the normal colonic flora but leaves C. difficile spores intact. Those spores germinate, and with competitors gone, the bacterium produces toxins that inflame the colon. Roughly 500,000 Americans develop C. difficile infection each year, and 15,000 to 30,000 die from it, per CDC estimates.

Recurrence is the hard part. About 20 to 30 percent of patients relapse after a first treatment course, and the figure climbs toward 60 percent after a third. Each relapse is treated with more antibiotics, which deepens the dysbiosis and narrows the patient's remaining options. FMT interrupts that loop by rebuilding the community rather than suppressing one organism.

The mechanism runs through bile acids. Primary bile acids such as taurocholate trigger C. difficile spores to germinate. Secondary bile acids such as deoxycholate inhibit germination and suppress vegetative growth. A healthy microbiome converts the first into the second, partly through organisms such as Clostridium scindens, a pathway mapped by Buffie and colleagues in 2015. FMT restores that conversion, and colonization resistance returns within days.

Efficacy numbers are unusually strong for an infectious disease. In a 2013 trial by van Nood and colleagues, 81 percent of patients were cured after one infusion and 94 percent after a second. Real-world cure rates of 85 to 90 percent for recurrent infection are standard. Those figures are why regulators tolerate a treatment made from human waste.

Processing is where the bank does its real work. A donor produces 50 to 100 grams of stool per session. Staff dilute it in saline, blend it, filter out solids, and either use it fresh or freeze it at minus 80 degrees Celsius with glycerol. One donation typically yields enough material for one to three treatments.

In plain terms: the bank is not selling waste, it is selling a screened and standardized bacterial ecosystem.

Can You Get Paid to Donate Poop? What Banks Actually Pay

Payment exists, but it is modest and heavily structured. OpenBiome, the nonprofit stool bank in Massachusetts that popularized the model, has paid donors USD 40 per donation with a USD 500 monthly cap. Other US programs range from USD 25 to USD 50 per donation, and a few pay USD 20 to USD 30 for each sample that passes processing checks.

Three numbers govern donor pay: USD 25 to USD 50 per donation, a USD 200 to USD 500 monthly cap, and a requested schedule of 3 to 5 donations per week. A donor who hits a USD 500 cap every month earns at most USD 6,000 a year, and most part-time donors land between USD 1,000 and USD 3,000.

Not every program pays cash at all. Many hospital-based FMT services run donor registries that reimburse parking, mileage, and time at USD 20 to USD 75 per visit. Academic centers running clinical trials usually pay nothing beyond travel, because trial participants are research subjects rather than suppliers.

The payment is compensation, and legally it is not a sale of tissue. The 1984 National Organ Transplant Act bars payment for solid organs, but stool falls outside that statute, and no federal rule sets donor payment rates. Banks generally treat the money as taxable income for the donor, so a serious donor keeps records.

The value asymmetry is the part donors rarely see. Banked FMT material carries a list price of roughly USD 500 to USD 1,600 per treatment course at US hospitals. A single donation supplies material for one to three treatments, so one bowel movement becomes USD 500 to USD 4,800 of billable product. That gap covers donor screening, pathogen testing, anaerobic processing, freezer storage, and regulatory compliance, all of which cost far more than the stool itself.

Why Screening Rejects Nearly Everyone

Stool is easy to obtain; qualified stool is not. Banks reject 97 to 99 percent of applicants, and the barriers are cumulative rather than arbitrary. Each criterion removes a slice of the population, and the remaining pool is small.

The core criteria are narrow. Donors are typically 18 to 50 years old, with a body mass index under 30. They must have taken no antibiotics in the past 3 to 6 months and no travel to regions with high rates of resistant organisms in the past 6 months. Recent tattoos, piercings, or new sexual partners trigger a waiting period of 6 to 12 months. A history of irritable bowel syndrome, inflammatory bowel disease, diabetes, autoimmune disease, or major psychiatric illness is disqualifying.

Testing adds cost and time. A full donor workup runs 25 to 30 blood and stool tests, covering HIV, hepatitis A, B, and C, syphilis, HTLV, intestinal parasites, C. difficile itself, and multidrug-resistant organisms. Screening costs the bank USD 1,000 to USD 2,000 per accepted donor. Donors pay nothing, which is why any program charging a screening fee should be treated as fraudulent.

Because pathogens can be acquired after acceptance, donors are retested every 8 to 12 weeks. A course of antibiotics may suspend a donor for 2 to 6 weeks, or permanently if the bank cannot re-clear the sample. International travel, a gastrointestinal illness, or a new household pet can reset the clock.

The ideal donor profile is narrow and slightly counterintuitive. Banks favor lean, young adults with high fiber intake, diverse gut microbiota, and years without antibiotic exposure. Regular, predictable bowel habits matter more than enthusiasm. Someone with mild irritable bowel syndrome is excluded because the bank cannot rule out transferring a dysbiotic community along with the treatment.

In plain terms: a donor is not a supplier of a commodity but a long-term biological sample that must stay clean for months.

The Donor Timeline From Application to First Payment

Onboarding takes 4 to 10 weeks, and most of that is laboratory turnaround rather than paperwork. The table below shows a typical sequence at a US stool bank.

Two details catch new donors. First, some banks pay only for donations that pass processing checks, so a low-volume or contaminated sample earns nothing. Second, donors usually must live within about 45 minutes of the facility, because material has to be processed within hours of passage.

Stool Donation Compared With Other Paid Donations

Stool donation pays well per hour on paper and poorly in practice, because of caps, commute time, and rejection rates. The comparison below uses typical 2025 to 2026 US program figures.

A stool donation session itself takes 20 to 30 minutes, so a USD 40 payment looks like USD 80 an hour. Add a 30-minute round trip three to five times a week, plus a monthly cap, and effective pay drops toward USD 20 to USD 25 an hour. Plasma pays less per session but has no comparable rejection rate, which is why it remains the more reliable option for most people.

Misconceptions, Risks, and Regulatory Limits

The biggest misconception is that stool banks buy a raw material. They pay for a donor's time, and the screening burden sits with the bank. That distinction matters because it explains why pay stays low while the final product is expensive.

FMT is regulated as a biological product rather than a supplement. The FDA has exercised enforcement discretion for FMT used to treat C. difficile infection that does not respond to standard therapy. Its 2022 final guidance pushed banks toward stricter donor screening for multidrug-resistant organisms and required an investigational new drug application for other uses. That guidance is the reason MDRO testing now sits inside every donor panel.

The safety record has real blemishes. In 2019 the FDA reported invasive infections caused by extended-spectrum beta-lactamase producing E. coli transmitted through FMT, including one death. In 2023 the agency flagged Shiga toxin producing E. coli in trial material. Serious adverse events remain rare relative to the number of procedures, but they explain the intense donor screening.

The market is also shifting. The FDA approved Rebyota in December 2022 and Vowst in April 2023, two standardized microbiota products made from screened human stool. These are manufactured, dosed, and regulated like drugs. If they capture recurrent C. difficile treatment, demand for raw banked stool may fall, though the timeline for that is genuinely uncertain.

Other claims outrun the evidence. FMT for ulcerative colitis, hepatic encephalopathy, obesity, and immunotherapy response is under investigation, not established practice. Donors recruited for those studies are research participants and are usually unpaid. The hypothesis that stool donation could transmit weight-related traits is a caution flagged in guidance, not a demonstrated effect.

In plain terms: the science is solid for one disease, promising for a few others, and unproven elsewhere.

What to Actually Do

Start with institutions rather than advertisements. Search for fecal microbiota transplantation programs at academic medical centers near you, and check whether a licensed stool bank operates in your region. Anyone promising fast cash from your stool is almost certainly not a bank.

Six steps make the process smoother:

• Contact two or three academic FMT programs and one nonprofit stool bank before answering any online ad.
• Ask whether the program operates under an FDA investigational new drug application and who pays for screening. Legitimate banks cover all screening costs.
• Ask whether pay is per donation, per accepted sample, or per month, and what the monthly cap is.
• Keep a 90-day record of antibiotics, international travel, tattoos, piercings, new sexual partners, and gastrointestinal symptoms before applying.
• Confirm you live within roughly 45 minutes of the facility, because donations are needed 3 to 5 times a week and material must be processed within hours.
• Walk away from any program that charges a screening fee, asks you to ship stool by mail, or promises USD 1,000 a week.

Expect a 4 to 10 week onboarding, budget the money as modest taxable income, and keep a copy of every test result. Donors who clear screening often stay eligible for a year or more, which is where the USD 1,000 to USD 6,000 annual range becomes realistic rather than theoretical.